. Author manuscript; available in PMC: 2021 Dec 14.

Published in final edited form as: JACC Clin Electrophysiol. 2020 Sep 16;6(13):1658–1668. doi: 10.1016/j.jacep.2020.06.036

Table 3.

Association of Warfarin Exposure with Outcomes in Time Varying Covariate Cox Regression model analyses.

Outcome	Model 1		Model 2		Model 3		Model 4
Outcome	no-warfarin	Warfarin exposed	no-warfarin	Warfarin exposed	no-warfarin	Warfarin exposed	no-warfarin	Warfarin exposed
CVA, Hazard ratio (95% CI)	Ref	1.10 (1.04–1.17)	Ref	1.13(1.07–1.19)	Ref	1.23(1.16–1.30)	Ref	1.23(1.15–1.32)
CVA-hospitalization, Hazard ratio (95% CI)	Ref	1.26(1.18–1.34)	Ref	1.29(1.20–1.38)	Ref	1.38(1.28–1.48)	Ref	1.33(1.221.46)
Major Bleeding Event, Hazard ratio (95% CI)	Ref	1.27 (1.211.33)	Ref	1.28 (1.22 to 1.35)	Ref	1.36(1.291.44)	Ref	1.34(1.251.43)
Major Bleeding Event-Hospitalization, Hazard ratio (95% CI)	Ref	1.47 (1.391.56)	Ref	1.50(1.41–1.59)	Ref	1.56(1.47–1.67)	Ref	1.49(1.381.61)
All-cause post dialysis mortality, Hazard ratio (95% CI)	Ref	0.87(0.84–0.90)	Ref	0.92(0.90–0.96)	Ref	0.94(0.90–0.97)	Ref	0.93 (0.890.98)

Ref, reference; CVA, cerebrovascular accident; CI, confidence interval

Model 1- unadjusted

Model 2- adjusted for age, sex, race, ethnicity, marital status

Model 3- adjusted for age, sex, race, ethnicity, marital status, comorbidities, chadvasc score, Charlson comorbidity index and medications

Model 4- adjusted for age, sex, race, ethnicity, marital status, comorbidities, chadvasc score, Charlson comorbidity index, medications, systolic and diastolic blood pressures, serum/blood hemoglobin values and estimated glomerular filtration rates